• Diet-induced obesity (DIO) causes tau phosphorylation in wild-type mouse hippocampus.
Introduction
Alzheimer disease (AD) is the most common cause of dementia, with the number of patients increasing steadily worldwide [5] . Accumulating evidence indicates that obesity raises the risk of developing AD, independent of other factors [6, 17, 20] . Consequently, the risk of developing AD may be decreased by reducing obesity, a preventable disease. However, little is known about the causative link between obesity and AD. AD is pathologically characterized by the extracellular deposition of amyloid ␤ (A␤) as senile plaques, as well as the intracellular accumulation of hyperphosphorylated aggregated tau in the form of neurofibrillary tangles [8] . Recent studies have shown that diet-induced obesity (DIO) enhances AD-related pathology in transgenic mouse models of AD. DIO increases A␤ deposition and memory deficits in APP SWE transgenic mice expressing human APP695 containing the Swedish double mutation (KM670/671NL) [14, 15] . DIO also exacerbates tau phosphorylation in the hippocampus and impairs learning ability in tau transgenic mice [12] . These studies clearly show that DIO accelerates AD-associated pathological processes and diminishes cognitive function. Furthermore, APP SWE transgenic mice fed a high-fat diet and given physical exercise show less A␤ deposition than their counterparts fed a high-fat diet without physical exercise [14, 15] . These findings indicate that physical exercise can prevent obesity-induced pathological changes in AD mouse models. Additionally, in WT rats, DIO increases glial fibrillary acidic protein (GFAP) expression in the hippocampus [7] and impairs cognitive function [11] . However, it remains unclear whether DIO enhances AD-related pathological processes in WT mice.
The purpose of this study was to examine the effects of DIO on tau pathology using immunohistochemistry in WT mice. We also assessed the protective effect of voluntary exercise on the pathological changes induced by DIO.
Material and methods
WT female mice (B6C3H/F1) were divided into high calorie diet (Fat = 15.3%; 4.15 Cal/g, Quick Fat (Clea Japan Inc., Tokyo, Japan))-fed (n = 21) and standard diet (Fat = 4.5%; 3.3 Cal/g)-fed (SD, n = 6) groups. The high calorie diet group was subdivided into no-exercise (HCD, n = 17) and exercise (HCD + Ex, n = 4) groups. Mice in the HCD and HCD + Ex groups were fed a high calorie diet, starting at the age of 12 weeks. HCD + Ex group mice were housed in cages equipped with a running wheel (Clea Japan Inc., Japan) for voluntary exercise from the age of 8 weeks. The average amount of exercise was 1.1 ± 0.4 × 10 4 rounds/day (≈7.4 ± 2.5 km/day, mean ± SD). Body weight was measured every 4 weeks. Animals were anesthetized by intraperitoneal injection of 1% xylocaine at the age of 40 weeks and decapitated. The body temperature was controlled during the anesthesia using a heating pad. We used PS19 tauopathy model mice, which carry the human tau gene with a P301S mutation [21] , as positive controls for evaluating tau pathology. In all experiments, we used only female mice because there was a large difference in body weight between male and female, and the body weight of male mice varied much more widely than that of female mice in a preliminary experiment.
Intraperitoneal glucose tolerance tests (IGTTs) were performed at 40 weeks of age. On the night before the IGTTs, food was removed at 6:00 PM, and the following morning, mice were given a single dose, by intraperitoneal injection, of glucose (2 g/kg body weight). Blood samples were collected from the tail vein immediately before glucose administration and at 15, 30, 60 and 120 min after gavage. Blood glycemic content was assessed using Glutest Ace R (Sanwa Kagaku Kenkyusho Co., Ltd, Nagoya, Japan), following the manufacturer's instructions. For analyses, glucose responses over time were integrated to determine the area-under-the-curve.
Tissue preparation and immunohistochemical analysis were performed as previously described [21] . Briefly, mice were deeply anesthetized and transcardially perfused with 15 ml phosphatebuffered saline (PBS). The brains were removed, immersion-fixed for 24 h in 4% paraformaldehyde/PBS, and stored in 15% sucrose/PBS at 4 • C until use. The brains were cut into 20-m-thick sections for immunohistochemical analysis. Free-floating sections were immunostained using streptavidin-biotin peroxidase.
The following antibodies were used in this study: mAb AT8 (1:100; Innogenetics, Gent, Belgium), mAb AT180 (1:100; Innogenetics), mAb S422 (1:100; Invitrogen, CA, USA), anti-glial fibrillary acidic protein (1:1000; Dako, CA, USA), anti-Iba-1 (1:1000; Wako, Osaka, Japan), anti-leptin receptor M18 (1:100; Santa Cruz Biotechnology, CA, USA), and anti-leptin receptor C14104 (1:100; Neuromics, MN, USA).
Images were captured with a Nikon eclipse 80i microscope and a Nikon DXM 1200C digital camera. To measure the area occupied by S422-, GFAP-, Iba-1-and M18-positive cells in the hippocampus and amygdala we obtained three images each of the CA1, CA3 and dentate gyrus regions of the hippocampus and five images each of the amygdala for each animal. The quantification of the positively labeled areas was performed using Photoshop (Adobe Systems, CA, USA). The number of neurons and the number of GFAP-and Iba-1 positive cells were measured manually using digital photomicrographs. Quantification results were analyzed using one-way ANOVA, followed by Tukey's post hoc test or Scheffe's post hoc test. Results were expressed as mean ± SD, and differences with P < 0.05 were considered significant.
Results
To evaluate the effect of diet and exercise, we measured body weight gain every 4 weeks. After 20 weeks of age, the body weight of HCD mice was significantly increased compared with SD mice or HCD + Ex mice (Fig. 1A) . To estimate glucose tolerance, we performed IGTTs on the three groups. Although serum glucose at 60 min was slightly elevated in the HCD group compared with the SD or HCD + Ex group, the area-under-the-curve was not significantly different among the three groups (Fig. 1B) . These findings suggest that glucose metabolism is not significantly perturbed in HCD mice.
To assess the effect of DIO on the tau phosphorylation, the neuropathological hallmarks of AD, we performed immunohistochemistry using several phosphorylation-specific tau antibodies; S422 (phospho-Ser422), AT-8 (phospho-Ser202 and phosphoThr205) and AT-180 (phospho-Thr231). Sections from the three different groups in WT mice were not labeled with AT-8 (Fig. 1C) or AT-180 (Fig. 1D) . Interestingly, dendrites in the CA1 region and mossy fiber in the CA3 region were slightly stained with S422 in HCD mice ( Fig. 1G and H ), but not in SD ( Fig. 1E and F) or HCD + Ex ( Fig. 1I and J) mice. As positive controls, perikarya and neurites in the CA1 of the hippocampus from the 24-week-old PS19 mice were strongly stained with AT-8 (Fig. 1C, inset) , AT-180 (Fig. 1D,  inset ), or S422 (Fig. 1E, inset) , respectively. Quantitative analysis revealed that the percentage of the area occupied by S422-positive cells is higher in HCD mice than in SD or HCD + Ex mice (Fig. 1K) . We also examined the amygdala and other brain regions, but they were not stained with S422, AT-8 or AT-180. It is known that tau phosphorylation occurs in neurites in early phase [18] . From these results, we conjectured that DIO can at least partially induce tau phosphorylation in the hippocampus in WT mice. Next, to assess neurodegeneration, we counted the number of neurons in the hippocampus. The number of neurons in the hippocampus was not significantly different among the three different groups (data not shown), suggesting that neurodegeneration was not present.
Because astrogliosis parallels the distribution of tau phosphorylation in neurodegenerative diseases [2, 19] , we performed immunohistochemistry with an antibody to GFAP. The number of GFAP-immunoreactive astrocytes in the CA1 and CA3 regions of the hippocampus was significantly increased (Fig. 2B and E) and some astrocytes displayed hypertrophic changes (Fig. 2B , E, inset) in HCD mice compared with SD ( Fig. 2A and D) or HCD + Ex mice (Fig. 2C  and F) . Similar changes were observed in the amygdala (Fig. 2G-I ). Quantitative analysis revealed that the percentage of the area occupied by GFAP-positive cells (Fig. 2P ) and the number of astrocytes The CA1 and CA3 regions of the hippocampus from SD (E and F), HCD (G and H) and HCD + Ex (I and J) mice are stained S422 antibody (against pSer422). Dendrites in the CA1 region (E) and mossy fiber in the CA3 region (F) are stained with S422 in HCD mice, but not in SD or HCD + Ex mice. Perikarya and neurites in the CA1 of the hippocampus from the 24-week-old PS19 mice were strongly stained with AT-8 (C, inset), AT-180 (D, inset), or S422 (E, inset), respectively. The graph shows that the area of S422 positive cells is higher in HCD mice than in SD or HCD + Ex mice (K). Scale bars: 50 m (C-J). Data are mean ± SD. *P < 0.05, HCD vs. SD or HCD + Ex mice. **P < 0.01, HCD vs. SD or HCD + Ex mice.
( Fig. 2Q) were increased in the hippocampus and amygdala of HCD mice compared with SD or HCD + Ex animals. Because microgliamediated neuroinflammation is implicated in the pathogenesis of neurodegenerative diseases [1, [21] [22] [23] , we assessed microglial activation using an anti-Iba-1 antibody. In HCD mice, the number of microglia was increased in the hippocampus (Fig. 2J-L ) and the amygdala (Fig. 2M-O) , paralleling the distribution of astrogliosis. Although significant microglial morphological differences were not seen among the three different groups (Fig. 2J-O, inset) , the percentage of the area occupied by Iba-1-positive cells (Fig. 2R ) and the number of microglia (Fig. 2S) were increased in the hippocampus and amygdala of HCD mice compared with SD or HCD + Ex animals. These findings of increased astrogliosis and microgliosis in the absence of neuronal loss suggest that the activation of astrocytes and microglia in HCD mice is not secondary to the neurodegenerative changes, but might be directly caused by DIO. The results also indicate that microglial activation is relatively mild compared with astroglial activation.
As described above, we observed tau phosphorylation and astrogliosis in the HCD mouse hippocampus. Our previous study using PS19 mice showed that DIO enhanced tauopathy and neuroinflammation through the activation of astrocytic leptin receptor (LepR) (Unpublished data). Therefore, focusing on the role of leptin receptor in the WT mice, we performed immunohistochemistry for LepR in the hippocampus where the overt astrogliosis occurred. LepR can be divided into two isoforms; long form (LepRl) and short form (LepRs). We used anti-M18 antibody, which recognizes the short cytoplasmic form of membrane-bound LepR [9] . M18-positive cells were seen mainly in the hippocampus (Fig. 3A-C) and the hypothalamus (data not shown). M18-positive cells were considered astrocytes on a morphological basis, and double-labeled hippocampal sections demonstrated that all M18-expressed cells were GFAP-positive astrocytes (Fig. 3D-F) . To quantify the LepRs expression, we standardized the M18-positive area divided by the GFAP-positive area because LepRs was expressed in astrocytes and HCD increased the area of astrocytes. As shown in Fig. 3G , the expression of astrocytic LepRs was significantly increased in the hippocampus of HCD mice compared with SD or HCD + Ex animals. This indicated that DIO caused not only astrogliosis, but also increase expression of LepRs. We also performed immunohistochemistry with a CH14104 antibody, which recognizes the unique LepRl cytoplasmic tail sequence, but staining was barely visible in the hippocampus (data not shown).
Discussion
Our results demonstrate that persistent obesity from early life induces tau phosphorylation in the hippocampus accompanied by enhanced astroglial LepRs expression, which might be directly related to obesity. Although phosphorylated tau staining was only seen in the hippocampus, astroglial activation and microgliosis were seen in the amygdala and hippocampus, both regions in which tau pathology is preferentially seen in AD. The difference in distribution suggests that astroglial activation and microgliosis might precede tau phosphorylation. Because there was no evidence of neurodegeneration in the hippocampus even though tau phosphorylation was observed in this region, obesity itself may not induce the entire pathological process of tau-phosphorylation-related neurodegeneration or might require a much longer period of time to induce neurodegeneration. In this study, tau phosphorylation was observed only at Ser422, but not at Ser202/Thr205. There is a consistent pattern of tau phosphorylation that corresponds to the degree of neuronal cytopathology during neurofibrillary tangle formation [3] . Ser422 is phosphorylated earlier than Ser202/Thr205, which is recognized by AT-8 [3] . In addition, tau phosphorylation is detected in neurites earlier than in cell body in early phase [18] . Therefore, we presumably observed one of the earliest tau pathological changes.
Recently, Jayaram et al. that reported that DIO did not increase GFAP expression in astrocyte-specific LepR knockout mice; rather, it reduced [10] . Although they did not mention the isoform of astrocytic LepR, our study showed that LepRs, not LepRl, was expressed in astrocytes. Therefore, astrocytic LepRs is thought to be involved in the process of DIO-induced astrogliosis. Furthermore, a recent study showed that the LepRs functions as a proinflammatory factor during leptin resistance [13] . Thus, our results suggest that DIO might enhance astroglial leptin sensitivity and activation by up-regulating the LepRs, which in turn might promote tau phosphorylation by enhanced inflammatory responses. However, the link between astroglial activation, enhanced LepRs expression and inflammation remains unclear and requires further investigation.
Recent studies have shown differing results on whether DIO enhances tau phosphorylation in WT mice [4, 12, 16] . Both Moroz's study (60%-fat chow, fed for 4 months from 1 month of age) and Leboucher's study (59%-fat chow, fed for 5 months from 2 months of age) reported that DIO increased the level of tau but did not induce tau phosphorylation [12, 16] . On the other hand, Bhat's study (21%-fat chow, fed for 2 months from 4 months of age) and our present study (15.3%-fat chow, fed for 7 months from 3 months of age) showed that DIO increased tau phosphorylation in WT mice [4] . The discrepancy in results probably arises from food nutrition, feeding duration, or both. Interestingly, studies feeding mice a mildly high-fat diet demonstrated tau phosphorylation. We therefore conjecture that DIO itself can promote a subset of tau phosphorylation but depends on conditions which remain unclear.
Some studies have shown that physical exercise alleviates pathological changes elicited by DIO in the AD model without reduction in body weight [14, 15] . Our results in WT mice are in line with the findings in these reports; voluntary exercise inhibits DIOinduced tau phosphorylation, astroglial activation and microgliosis in the hippocampus. However, it remains unclear whether voluntary exercise directly alleviates these pathological changes in this study because the body weight of mice in the HCD + Ex group was significantly lower than that of mice in the HCD group. Moreover, HCD mice showed slight glucose intolerance and voluntary exercise mitigated the change. It is possible that improvement of obesity and/or glucose intolerance ameliorated these pathological changes.
In conclusion, the present study demonstrates that DIO at least partially causes tau phosphorylation and that astrocytic LepRs may play a role in the pathogenetic process in WT mouse hippocampus. While obesity itself does not appear to directly cause neurodegeneration, it might accelerate pathological processes in neurodegenerative disorders. Our findings also indicate that physical exercise might be a promising strategy for the prevention of AD in patients with obesity.
